Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?
作者信息
Cencini Emanuele, Fabbri Alberto, Raspadori Donatella, Gozzetti Alessandro, Bocchia Monica
机构信息
Unit of Hematology, Azienda Ospedaliera Universitaria Senese & University of Siena, Siena, Italy.
出版信息
Blood Res. 2021 Dec 31;56(4):333-334. doi: 10.5045/br.2021.2020322.
Abstract
摘要
相似文献
1
Tp53 disruptions: is there a marker of poor prognosis in chronic lymphoproliferative disorders?Tp53 功能破坏：慢性淋巴细胞增殖性疾病中是否存在预后不良的标志物？
Blood Res. 2021 Dec 31;56(4):333-334. doi: 10.5045/br.2021.2020322.
2
TP53 deletions but not trisomy 12 are adverse in B-cell lymphoproliferative disorders.在B细胞淋巴增殖性疾病中，TP53缺失而非12号染色体三体具有不良影响。
Cancer Genet Cytogenet. 2000 Jun;119(2):146-54. doi: 10.1016/s0165-4608(99)00234-4.
3
Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients.在先前治疗的慢性淋巴细胞白血病患者中，TP53 的失活与疾病进展和低 miR-34a 表达相关。
Blood. 2013 May 2;121(18):3650-7. doi: 10.1182/blood-2012-10-458695. Epub 2013 Mar 22.
4
and alterations in diffuse large B-cell lymphoma: prognostic markers identified via exome analysis of cases with extreme prognosis.弥漫性大B细胞淋巴瘤的改变：通过对预后极差病例的外显子组分析确定的预后标志物。
Oncotarget. 2018 Apr 13;9(28):19555-19568. doi: 10.18632/oncotarget.24656.
5
Association between Mutation and Expression of as a Potential Prognostic Marker of Triple-Negative Breast Cancer.作为三阴性乳腺癌潜在预后标志物的 突变与表达的相关性研究。
Cancer Res Treat. 2016 Oct;48(4):1338-1350. doi: 10.4143/crt.2015.430. Epub 2016 Feb 18.
6
TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.TP53突变是淋巴结阴性和阳性乳腺癌预后不良的独立预后标志物。
Acta Oncol. 2000;39(3):327-33. doi: 10.1080/028418600750013096.
7
Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.靶向 T 细胞淋巴增生性疾病的 JAK/STAT 通路。
Curr Hematol Malig Rep. 2019 Dec;14(6):570-576. doi: 10.1007/s11899-019-00545-5.
8
NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment.接受一线治疗的慢性淋巴细胞白血病患者的NOTCH1、SF3B1、BIRC3和TP53突变：与生物学参数及治疗反应的相关性
Leuk Lymphoma. 2014 Dec;55(12):2785-92. doi: 10.3109/10428194.2014.898760.
9
Novel prognostic molecular factors: a quantum leap in the field of chronic lymphocytic leukemia.新型预后分子因素：慢性淋巴细胞白血病领域的一次巨大飞跃。
Folia Histochem Cytobiol. 2017;55(3):95-106. doi: 10.5603/FHC.a2017.0019. Epub 2017 Oct 10.
10
TP53 mutation and survival in chronic lymphocytic leukemia.TP53 突变与慢性淋巴细胞白血病的生存。
J Clin Oncol. 2010 Oct 10;28(29):4473-9. doi: 10.1200/JCO.2009.27.8762. Epub 2010 Aug 9.
引用本文的文献
1
The Advances and Biomedical Applications of Imageable Nanomaterials.可成像纳米材料的进展与生物医学应用
Front Bioeng Biotechnol. 2022 Jul 5;10:914105. doi: 10.3389/fbioe.2022.914105. eCollection 2022.
本文引用的文献
1
Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey.伊布替尼治疗32例慢性淋巴细胞白血病和各种B细胞淋巴瘤患者的安全性和疗效分析：来自土耳其一项单中心研究的真实世界数据。
Blood Res. 2020 Dec 31;55(4):206-212. doi: 10.5045/br.2020.2020158.
2
Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis.复发/难治性边缘区淋巴瘤中依鲁替尼的持久反应：长期随访和生物标志物分析
Blood Adv. 2020 Nov 24;4(22):5773-5784. doi: 10.1182/bloodadvances.2020003121.
3
Association of TP53 Mutations with Response to Anlotinib Treatment in Advanced Non-Small Cell Lung Cancer.TP53突变与晚期非小细胞肺癌患者对安罗替尼治疗反应的相关性
Onco Targets Ther. 2020 Jul 7;13:6645-6650. doi: 10.2147/OTT.S257052. eCollection 2020.
4
somatic mutations are associated with poor survival in non-small cell lung cancer patients who undergo immunotherapy.体细胞突变与接受免疫治疗的非小细胞肺癌患者的不良预后相关。
Aging (Albany NY). 2020 Jul 22;12(14):14556-14568. doi: 10.18632/aging.103502.
5
Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement.以伊布替尼为基础的疗法用于治疗累及中枢神经系统的边缘区淋巴瘤。
Leuk Lymphoma. 2020 Dec;61(12):2980-2984. doi: 10.1080/10428194.2020.1791849. Epub 2020 Jul 10.
6
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.边缘区淋巴瘤：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2020 Jan;31(1):17-29. doi: 10.1016/j.annonc.2019.10.010. Epub 2019 Dec 4.
7
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.DYNAMO 研究：杜韦利昔布（IPI-145）治疗难治性惰性非霍奇金淋巴瘤的 II 期研究。
J Clin Oncol. 2019 Apr 10;37(11):912-922. doi: 10.1200/JCO.18.00915. Epub 2019 Feb 11.
8
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis.依鲁替尼治疗复发/难治性套细胞淋巴瘤：汇总分析的3.5年延长随访结果
Haematologica. 2019 May;104(5):e211-e214. doi: 10.3324/haematol.2018.205229. Epub 2018 Nov 15.
9
Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.解析 TP53 突变慢性淋巴细胞白血病对伊布替尼治疗反应不佳的原因。
Br J Haematol. 2019 Feb;184(3):392-396. doi: 10.1111/bjh.15613. Epub 2018 Oct 18.
10
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.维奈托克单药治疗在接受布鲁顿酪氨酸激酶抑制剂治疗后复发、难治性套细胞淋巴瘤患者中的疗效。
Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6.
Zotero 插件